The aim of minimal residual disease (MRD) studies in patients with acute leukemia is to measure initial treatment response accurately, provide an assessment of the residual leukemic burden throughout therapy and detect relapse early. Therefore, information resulting from MRD monitoring can substantially improve many facets of clinical management. Methods for MRD detection, namely flow cytometry and PCR, have been applied to study the remission status of thousands of patients with acute lymphoblastic leukemia and acute myeloid leukemia. Collectively, the data indicate that MRD is a powerful prognostic indicator and an indispensable parameter for risk-adapted therapy. The current status of MRD in acute leukemia is briefly reviewed in this paper.

对急性白血病患者进行微小残留病 (MRD) 研究的目的是准确测量初始治疗反应，评估整个治疗过程中的残留白血病负担并及早发现复发。因此，MRD 监测产生的信息可以显着改善临床管理的许多方面。MRD检测方法，即流式细胞术和PCR，已被应用于研究数千名急性淋巴细胞白血病和急性髓细胞白血病患者的缓解状态。总的来说，数据表明 MRD 是一个强有力的预后指标，也是风险适应治疗不可或缺的参数。本文简要回顾了急性白血病MRD的现状。